Autoimmune hepatitis: Clinical characteristics and predictors of biochemical response to treatment

Abstract

Background and ObjectivesAutoimmune hepatitis (AIH) is an important cause of chronic liver disease. Aim of this study was to evaluate the clinical characteristics and factors predicting response to treatment in patients with AIH.MethodsIn this prospective observational study, all patients diagnosed with AIH from 2017 to 2019 were included. Biochemical response to the treatment was checked three months after the start of the treatment. Response was considered good if transaminases normalized, or poor if either remained persistently elevated or improved partially.ResultsOf the total 56 patients, 41 (73.2%) were females. Mean age was 29.5 (±16.9) years. About half (53.6%; n = 30) the patients were aged < 25 years and majority [47 (83.9%)] were cirrhotic. Autoimmune serology was negative in 20 (35.7%). Seronegativity was associated with severe necroinflammation (P = 0.015) and esophageal varices (P = 0.021). Response to treatment was good in 34 (60.7%). Bivariate analysis showed that good response to treatment was associated with pre-treatment serum IgG level > 20 g/L (P = 0.024), presence of pseudorosettes on histopathology (P = 0.029) and three months post-immunosuppression serum total bilirubin < 2mg/dL (P < 0.001). Multivariate logistic regression analysis showed that only pre-treatment serum IgG >20 g/L (P = 0.038) and post-treatment serum total bilirubin <2 mg/dL (P = 0.004) were independent predictors of good response to treatment.ConclusionMajority of AIH patients in our study were young and cirrhotic. A negative autoimmune serology does not rule out AIH and liver biopsy may be required to confirm the diagnosis. Seronegative AIH rapidly progresses to advanced liver disease. Response to treatment is good with pre-treatment IgG > 20g/L and post-treatment total bilirubin < 2 mg/dL.

The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Immune Cell Infiltration in Hepatocellular Carcinoma

“…Tumor immunotherapy is considered as a promising method for tumor treatment, and it has become an important method and research focus of tumor treatment [ 31 , 32 ]. Through the analysis of immune-related functions, it could be found that the expression of these 13 immune-related functions was all significantly different between high- and low-risk groups ( P < 0.01), and they consistently showed a negative correlation in the high-risk groups ( Figure 11(a) ).…”

Acute-on-Chronic Liver Failure: Causes, Clinical Parameters, and Predictors of Mortality

“…Kulkarni et al (2018) [ 16 ] observed median ages of 42 years for those who survived and 47 years for those who did not (p=0.667) [ 16 , 17 ]. Tasneem et al (2017) [ 7 ] reported that individuals over 40 years exhibited a higher risk of mortality (p=0.036, Odds Ratio [OR] = 0.325). These findings collectively indicate that age alone may not be a dependable predictor of mortality in ACLF.…”

“…Chronic liver diseases are predominantly caused by chronic hepatitis B and C virus infections, particularly in regions such as Pakistan [ 7 ]. ACLF acute exacerbations may result from hepatic events such as acute viral hepatitis or non-hepatic sources like respiratory or urinary infections, and non-infectious factors including adverse drug reactions and surgical complications.…”

Comprehensive succinylome analyses reveal that hyperthermia upregulates lysine succinylation of annexin A2 by downregulating sirtuin7 in human keratinocytes

“…PTMs are important components regulating microbial resistance and immunity. [29,30] New emerging evidences support that PTMs serve as interfaces between viruses, restriction factors, and cellular defense mechanisms, providing potential drug targets for future immunoregulatory therapy. [31] Many restriction factors of viruses, such as IFITM3/2, APOBEC, and SAMHD1, can be subjected to phosphorylation.…”